Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Maldarelli Website

Frank Maldarelli, M.D., Ph.D.

Selected Publications

1)  Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors JW, Kearney MF, Coffin JM, Hughes SH.
HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells.
Science. 345: 179-83, 2014.
2)  Maldarelli F, Kearney M, Palmer S, Stephens R, Mican J, Polis MA, Davey RT, Kovacs J, Shao W, Rock-Kress D, Metcalf JA, Rehm C, Greer SE, Lucey DL, Danley K, Alter H, Mellors JW, Coffin JM.
HIV Populations Are Large and Accumulate High Genetic Diversity in a Nonlinear Fashion.
J. Virol. 87: 10313-23, 2013.
3)  McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F.
Short-Course Raltegravir Intensification Does Not Reduce Persistent Low-Level Viremia in Patients with HIV-1 Suppression during Receipt of Combination Antiretroviral Therapy.
Clin Infect Dis. 50: 912-919, 2010.
4)  Josefsson L, Palmer S, Faria NR, Lemey P, Casazza J, Ambrozak D, Kearney M, Shao W, Kottilil S, Sneller M, Mellors J, Coffin JM, Maldarelli F.
Single Cell Analysis of Lymph Node Tissue from HIV-1 Infected Patients Reveals that the Majority of CD4(+) T-cells Contain One HIV-1 DNA Molecule.
PLoS Pathog. 9: e1003432, 2013.
5)  Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O'Shea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, Mellors JW, Siliciano RF, Maldarelli F.
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.
Proc. Natl. Acad. Sci. U.S.A. 106: 9403-8, 2009.
6)  Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW.
ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia.
PLoS Pathog. 3: e46, 2007.
7)  Klase Z, Yedavalli VS, Houzet L, Perkins M, Maldarelli F, Brenchley J, Strebel K, Liu P, Jeang KT.
Activation of HIV-1 from Latent Infection via Synergy of RUNX1 Inhibitor Ro5-3335 and SAHA.
PLoS Pathog. 10: e1003997, 2014.
8)  De Ravin SS, Gray JT, Throm RE, Spindler J, Kearney M, Wu X, Coffin JM, Hughes SH, Malderelli F, Sorrentino BP, Malech HL.
False-Positive HIV PCR Test Following Ex Vivo Lentiviral Gene Transfer Treatment of X-linked Severe Combined Immunodeficiency Vector.
Mol. Ther. 22: 244-5, 2014.
9)  Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O'Shea A, Rehm C, Poethke C, Kovacs N, Mellors JW, Coffin JM, Maldarelli F.
Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy.
PLoS Pathog. 10: e1004010, 2014.
10)  Shao W, Kearney MF, Boltz VF, Spindler JE, Mellors JW, Maldarelli F, Coffin JM.
PAPNC, a novel method to calculate nucleotide diversity from large scale next generation sequencing data.
J. Virol. Methods. 203C: 73-80, 2014.
11)  Lau CY, Maldarelli F, Eckelman WC, Neumann RD.
Rational development of radiopharmaceuticals for HIV-1.
Nucl. Med. Biol. 41: 299-308, 2014.
12)  Wiegand A, Maldarelli F.
Single-Copy Quantification of HIV-1 in Clinical Samples.
Methods Mol. Biol. 1087: 251-60, 2014.
13)  Shao W, Boltz VF, Spindler JE, Kearney MF, Maldarelli F, Mellors JW, Stewart C, Volfovsky N, Levitsky A, Stephens RM, Coffin JM.
Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA.
Retrovirology. 10: 18, 2013.
14)  Delviks-Frankenberry KA, Lengruber RB, Santos AF, Silveira JM, Soares MA, Kearney MF, Maldarelli F, Pathak VK.
Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.
Virology. 435: 433-41, 2013.
15)  Andersson E, Shao W, Bontell I, Cham F, Cuong DD, Wondwossen A, Morris L, Hunt G, Sönnerborg A, Bertagnolio S, Maldarelli F, Jordan MR.
Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys.
Infect. Genet. Evol. 18C: 125-131, 2013.
16)  Sloan EA, Kearney MF, Gray LR, Anastos K, Daar ES, Margolick J, Maldarelli F, Hammarskjold ML, Rekosh D.
Limited Nucleotide Changes in the Rev Response Element (RRE) during HIV-1 Infection Alter Overall Rev-RRE Activity and Rev Multimerization.
J. Virol. 87: 11173-86, 2013.
17)  Casazza JP, Bowman KA, Adzaku S, Smith EC, Enama ME, Bailer RT, Price DA, Gostick E, Gordon IJ, Ambrozak DR, Nason MC, Roederer M, Andrews CA, Maldarelli FM, Wiegand A, Kearney MF, Persaud D, Ziemniak C, Gottardo R, Ledgerwood JE, Graham BS, Koup RA.
Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire.
J. Infect. Dis. 207: 1829-40, 2013.
18)  Wilson E, Tanzosh T, Maldarelli F.
HIV diagnosis and testing: what every healthcare professional can do (and why they should).
Oral Dis. 2012.
19)  Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, Dewar R, Marovich M, van Griensven F, Sekaly R, Pinyakorn S, Phanuphak N, Trichavaroj R, Rutvisuttinunt W, Chomchey N, Paris R, Peel S, Valcour V, Maldarelli F, Chomont N, Michael N, Phanuphak P, Kim JH.
Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection.
PloS one. 7: e33948, 2012.
20)  Kearney M, Spindler J, Wiegand A, Shao W, Anderson E, Maldarelli F, Ruscetti F, Mellors J, Hughes S, Le Grice S, Coffin J.
Multiple sources of contamination in samples from patients reported to have XMRV infection.
PLoS ONE. 7(2): e30889, 2012.
Full Text Article. [Journal]
21)  Palmer S, Boltz VF, Chow JY, Martinson NA, McIntyre JA, Gray GE, Hopley MJ, Mayers D, Robinson P, Hall DB, Maldarelli F, Coffin JM, Mellors JW.
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Antiviral therapy. 17: 327-336, 2012.
22)  Besson GJ, McMahon D, Maldarelli F, Mellors JW.
Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.
Clin. Infect. Dis. 54: 451-3, 2012.
23)  Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Mascio MD, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M, Telenti A, Lint CV, Verdin E, Woolfrey A, Zaia J, Barré-Sinoussi F.
Towards an HIV cure: a global scientific strategy.
Nature reviews. Immunology. 12: 607-614, 2012.
24)  Boltz VF, Ambrose Z, Kearney MF, Shao W, Kewalramani VN, Maldarelli F, Mellors JW, Coffin JM.
Ultrasensitive Allele-Specific PCR Reveals Rare Preexisting Drug Resistant Variants and a Large Replicating Virus Population in Macaques Infected with RT-SHIV.
J. Virol. 2012.
25)  Mens H, Kearney M, Wiegand A, Spindler J, Maldarelli F, Mellors JW, Coffin JM.
Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays.
J Vis Exp. 2011.
26)  Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, Adelsberger J, Baseler M, Maldarelli F, Davey R, Roby G, Rehm C, Lane C.
CD4 and CD8 T Cell Immune Activation during Chronic HIV Infection: Roles of Homeostasis, HIV, Type I IFN, and IL-7.
J. Immunol. 186: 2106-16, 2011.
27)  Cortez KJ, Maldarelli F.
Clinical Management of HIV Drug Resistance.
Viruses. 3: 347-78, 2011.
28)  Batorsky R, Kearney MF, Palmer SE, Maldarelli F, Rouzine IM, Coffin JM.
Estimate of effective recombination rate and average selection coefficient for HIV in chronic infection.
Proc. Natl. Acad. Sci. U.S.A. 108: 5661-6, 2011.
29)  Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S, Hu SL, Lifson JD, Kewalramani VN, Mellors JW, Coffin JM, Ambrose Z.
Genetic Diversity of Simian Immunodeficiency Virus Encoding HIV-1 Reverse Transcriptase Persists in Macaques despite Antiretroviral Therapy.
J. Virol. 85: 1067-76, 2011.
30)  Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, Dewar RL, Highbarger HC, Somaroo H, Sangweni P, Follmann DA, Pau AK.
Genotypic Resistance at Viral Rebound Among Patients Who Received Lopinavir/Ritonavir-Based or Efavirenz-Based First Antiretroviral Therapy in South Africa.
Journal of acquired immune deficiency syndromes (1999). 58: 304-308, 2011.
31)  Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, Brandt C, Vita J, Decker C, Sklar P, Bavaro M, Tasker S, Follmann D, Maldarelli F.
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: Results of a double-blind randomized placebo controlled clinical trial.
J Infect Dis. 203: 756-764, 2011.
32)  Josefsson L, King MS, Makitalo B, Brännström J, Shao W, Maldarelli F, Kearney MF, Hu WS, Chen J, Gaines H, Mellors JW, Albert J, Coffin JM, Palmer SE.
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule.
Proc. Natl. Acad. Sci. U.S.A. 108: 11199-204, 2011.
33)  Kearney MF, Lee K, Bagni RK, Wiegand A, Spindler J, Maldarelli F, Pinto PA, Linehan WM, Vocke CD, Delviks-Frankenberry KA, Devere White RW, Del Prete GQ, Mellors JW, Lifson JD, Kewalramani VN, Pathak VK, Coffin JM, Le Grice SF.
Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples.
Adv Virol. 2011: 272193, 2011.
34)  Maldarelli F.
Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.
Curr Opin HIV AIDS. 6: 49-56, 2011.
35)  Boyd SD, Maldarelli F, Sereti I, Ouedraogo GL, Rehm CA, Boltz V, Shoemaker D, Pau AK.
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
Antivir. Ther. (Lond.). 16: 257-61, 2011.
Full Text Article. [Journal]
36)  Kutty G, Achaz G, Maldarelli F, Varma A, Shroff R, Becker S, Fantoni G, Kovacs JA.
Characterization of the meiosis-specific recombinase Dmc1 of pneumocystis.
J. Infect. Dis. 202: 1920-9, 2010.
37)  Jordan MR, Kearney M, Palmer S, Shao W, Maldarelli F, Coakley EP, Chappey C, Wanke C, Coffin JM.
Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations.
J. Virol. Methods. 168: 114-20, 2010.
38)  Kearney M, Maldarelli F.
Current status of xenotropic murine leukemia virus-related retrovirus in chronic fatigue syndrome and prostate cancer: reach for a scorecard, not a prescription pad.
J. Infect. Dis. 202: 1463-6, 2010.
39)  Mens H, Kearney M, Wiegand A, Shao W, Schønning K, Gerstoft J, Obel N, Maldarelli F, Mellors JW, Benfield T, Coffin JM.
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.
J. Virol. 84: 12971-81, 2010.
40)  Boltz VF, Maldarelli F, Martinson N, Morris L, McIntyre JA, Gray G, Hopley MJ, Kimura T, Mayers DL, Robinson P, Mellors JW, Coffin JM, Palmer SE.
Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design.
J. Virol. Methods. 164: 122-126, 2010.
41)  Galli A, Kearney M, Nikolaitchik OA, Yu S, Chin MP, Maldarelli F, Coffin JM, Pathak VK, Hu WS.
Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication.
J. Virol. 84: 7651-61, 2010.
42)  Aloia AL, Sfanos KS, Isaacs WB, Zheng Q, Maldarelli F, De Marzo AM, Rein A.
XMRV: A new virus in prostate cancer?.
Cancer Res. 70: 10028-10033, 2010.
43)  Nies-Kraske E, Schacker TW, Condoluci D, Orenstein J, Brenchley J, Fox C, Daucher M, Dewar R, Urban E, Hill B, Guenaga J, Hoover S, Maldarelli F, Hallahan CW, Horn J, Kottilil S, Chun TW, Folino M, Palmer S, Wiegand A, O'Shea MA, Metcalf JA, Douek DC, Coffin J, Haase A, Fauci AS, Dybul M.
Evaluation of the Pathogenesis of Decreasing CD4(+) T Cell Counts in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Successfully Suppressive Antiretroviral Therapy.
J. Infect. Dis. 199: 1648-1656, 2009.
44)  Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM, Palmer S.
Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals.
J. Virol. 83: 2715-27, 2009.
45)  Porter BO, Anthony KB, Shen J, Hahn B, Keh CE, Maldarelli F, Blackwelder WC, Lane HC, Kovacs JA, Davey RT, Sereti I.
Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.
AIDS. 23: 203-12, 2009.
46)  Wilkin TJ, McKinnon JE, Dirienzo AG, Mollan K, Fletcher CV, Margolis DM, Bastow B, Thal G, Woodward W, Godfrey C, Wiegand A, Maldarelli F, Palmer S, Coffin JM, Mellors JW, Swindells S.
Regimen Simplification to Atazanavir-Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48-Week Clinical and Virologic Outcomes.
J. Infect. Dis. 2009.
47)  Shao W, Kearney M, Maldarelli F, Mellors JW, Stephens RM, Lifson JD, KewalRamani VN, Ambrose Z, Coffin JM, Palmer SE.
RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy.
Retrovirology. 6: 101, 2009.
48)  Delviks-Frankenberry KA, Nikolenko GN, Maldarelli F, Hase S, Takebe Y, Pathak VK.
Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.
J. Virol. 83: 8502-13, 2009.
49)  Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR.
Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
J. Acquir. Immune Defic. Syndr. 49: 513-9, 2008.
50)  Ramanathan R, Pau AK, Busse KH, Zemskova M, Nieman L, Kwan R, Hammer JH, Mican JM, Maldarelli F.
Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.
Clin. Infect. Dis. 47: e97-9, 2008.
51)  Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS.
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
Proc. Natl. Acad. Sci. U.S.A. 105: 3879-84, 2008.
52)  Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, Rehm C, O'Shea MA, Mican J, Packard BZ, Komoriya A, Palmer S, Wiegand AP, Maldarelli F, Coffin JM, Mellors JW, Hallahan CW, Follman DA, Connors M.
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.
Immunity. 29: 1009-21, 2008.
53)  Morse C, Maldarelli F.
Acquired immunodeficiency syndrome (AIDS). In: Immunology, Clinical Case Studies and Disease Pathophysiology (Strober W and Gottesman S, eds).
.: Wiley-Blackwell; 2009. p. . [Book Chapter]
54)  Kearney M, Palmer S, Maldarelli F, Shao W, Polis MA, Mican J, Rock-Kress D, Margolick JB, Coffin JM, Mellors JW.
Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase.
AIDS. 22: 497-501, 2008.
55)  Kutty G, Maldarelli F, Achaz G, Kovacs JA.
Variation in the major surface glycoprotein genes in Pneumocystis jirovecii.
J. Infect. Dis. 198: 741-9, 2008.
56)  Morse C, Maldarelli F.
Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?.
J. Infect. Dis. 195: 318-21, 2007.
57)  Nikolenko GN, Delviks-Frankenberry KA, Palmer S, Maldarelli F, Fivash MJ, Coffin JM, Pathak VK.
Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.
Proc. Natl. Acad. Sci. U.S.A. 104: 317-22, 2007.
58)  Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, Flanary L, Oswald K, Piatak M, Smedley J, Shao W, Bischofberger N, Maldarelli F, Kimata JT, Mellors JW, Hu SL, Coffin JM, Lifson JD, KewalRamani VN.
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.
J. Virol. 81: 12145-55, 2007.
59)  Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S, Ziermann R, Zhao RY, Jennings CL, Bremer J, Brambilla D, Mellors JW.
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.
J. Clin. Microbiol. 44: 2612-4, 2006.
60)  Bashirova AA, Bleiber G, Qi Y, Hutcheson H, Yamashita T, Johnson RC, Cheng J, Alter G, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, May M, Maldarelli F, Jacobson L, O'brien SJ, Telenti A, Carrington M.
Consistent Effects of TSG101 Genetic Variability on Multiple Outcomes of Exposure to Human Immunodeficiency Virus Type 1.
J. Virol. 80: 6757-63, 2006.
61)  Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, Mellors J, Morris L, Coffin J.
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
Proc Natl Acad Sci U S A. 103: 7094-9, 2006.
62)  Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, Falloon J, Davey RT, Dewar RL, Metcalf JA, Mellors JW, Coffin JM.
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.
AIDS. 20: 701-710, 2006.
63)  Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL.
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Pediatrics. 118: e711-8, 2006.
64)  Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK.
Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.
Proc Natl Acad Sci U S A. 102: 2093-8, 2005.
65)  Chen J, Dang Q, Unutmaz D, Pathak VK, Maldarelli F, Powell D, Hu WS.
Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factor.
J Virol. 79: 4140-9, 2005.
66)  Maldarelli F.
HIV drug resistance.
In: Textbook of Pediatric HIV Care. Zeichner SL, Read JS, eds: 334-354, 2005.
67)  Sklar PA, Masur H, Grubb JR, Voell J, Witek J, Ono A, Freed EO, Maldarelli F.
Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy.
AIDS. 19: 1109-11, 2005.
68)  Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL.
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Pediatrics. 116: e846-54, 2005.
69)  Dybul M, Nies-Kraske E, Dewar R, Maldarelli F, Hallahan CW, Daucher M, Piscitelli SC, Ehler L, Weigand A, Palmer S, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Beck I, Frenkel L, Baseler M, Coffin J, Fauci AS.
A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.
J Infect Dis. 189: 1974-82, 2004.
70)  Achaz G, Palmer S, Kearney M, Maldarelli F, Mellors JW, Coffin JM, Wakeley J.
A Robust Measure of HIV-1 Population Turnover within Chronically Infected Individuals.
Mol Biol Evol. 21: 1902-12, 2004.
71)  Kottilil S, Jagannatha S, Lu A, Liu S, McLaughlin M, Metcalf JA, Dewar R, Campbell C, Koratich C, Maldarelli F, Masur H, Polis MA.
Changes in Hepatitis C Viral Response After Initiation of Highly Active Antiretroviral Therapy and Control of HIV Viremia in Chronically Co-infected Individuals.
HIV Clin Trials. 5: 25-32, 2004.
72)  Maldarelli F.
Detection of HIV infection.
In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th ed, 2004.
73)  Dang Q, Chen J, Unutmaz D, Coffin JM, Pathak VK, Powell D, KewalRamani VN, Maldarelli F, Hu WS.
Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways.
Proc Natl Acad Sci U S A. 101: 632-7, 2004.
74)  Maldarelli F.
HIV drug resistance testing.
In: Handbook of Pediatric HIV Care. Cambridge University Press, 2003.
75)  Maldarelli F.
HIV-1 fitness and replication capacity: What are they and can they help in patient management?.
Curr Infect Dis Rep. 5: 77-84, 2003.
76)  Kottilil S, Chun TW, Moir S, Liu S, McLaughlin M, Hallahan CW, Maldarelli F, Corey L, Fauci AS.
Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function.
J Infect Dis. 187: 1038-45, 2003.
77)  Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM.
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.
J Clin Microbiol. 41: 4531-6, 2003.
78)  Palmer S, Kearney M, Maldarelli F, Kottilil S, Lucey D, Metcalf J, Rock D, VanHoutte M, Michels L, Hertogs K, Mellors J, Coffin J.
Genetics of HIV-1 populations in acute and chronic infection.
Antivir Ther. 7: S57, 2002.
79)  Maldarelli F.
Meeting report: Understanding Antiviral Drug Resistance. First HIV DRP Symposium, Chantilly, VA, USA, December 3-6, 2000.
Int Antiviral News. 9: 36-9, 2001.
80)  Favaro JP, Maldarelli F, Arrigo SJ, Schmidt MG.
Effect of rev on the cytoplasmic localization of intron-containing human immunodeficiency virus type 1 RNA.
Virology. 255: 237-49, 1999.
81)  Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R, Jeang KT.
Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb.
Mol Cell Biol. 18: 3620-32, 1998.
82)  Maldarelli F, Xiang C, Chamoun G, Zeichner SL.
The expression of the essential nuclear splicing factor SC35 is altered by human immunodeficiency virus infection.
Virus Res. 53: 39-51, 1998.
83)  Smith SM, Maldarelli F, Jeang KT.
Efficient expression by an alphavirus replicon of a functional ribozyme targeted to human immunodeficiency virus type 1.
J Virol. 71: 9713-21, 1997.
84)  Shibata R, Maldarelli F, Siemon C, Matano T, Parta M, Miller G, Fredrickson T, Martin MA.
Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing.
J Infect Dis. 176: 362-73, 1997.
85)  Freed EO, Englund G, Maldarelli F, Martin MA.
Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection.
Cell. 88: 171-3; discussion 173-4, 1997.
86)  Hori K, Hatfield D, Maldarelli F, Lee BJ, Clouse KA.
Selenium supplementation suppresses tumor necrosis factor alpha-induced human immunodeficiency virus type 1 replication in vitro.
AIDS Res Hum Retroviruses. 13: 1325-32, 1997.
87)  Fujita K, Maldarelli F, Silver J.
Bimodal down-regulation of CD4 in cells expressing human immunodeficiency virus type 1 Vpu and Env.
J Gen Virol. 77 ( Pt 10): 2393-401, 1996.
88)  Berthold E, Maldarelli F.
cis-acting elements in human immunodeficiency virus type 1 RNAs direct viral transcripts to distinct intranuclear locations.
J Virol. 70: 4667-82, 1996.
89)  Maldarelli F, Sato H, Berthold E, Orenstein J, Martin MA.
Rapid induction of apoptosis by cell-to-cell transmission of human immunodeficiency virus type 1.
J Virol. 69: 6457-65, 1995.
90)  Bhardwaj N, Maldarelli F, Mellors J, Coffin JM.
HIV-1 infection leads to increased transcription of HERV-K (HML-2) proviruses in vivo but not to increased virion production.
J. Virol. 2014.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/13/2014.